UCM ASX · Health Care

Uscom Ltd

Announcements, last 12 months: 20
Price sensitive, last 12 months: 13

Latest announcements

Released	Headline	Actions
16 Oct 2026, 4:26 PM	Long Term Suspended Entities Price sensitive
24 Aug 2026, 10:50 AM	Suspension from Official Quotation - Annual Listing Fees Price sensitive	AI summary
28 Jul 2026, 9:39 AM	Quarterly Activities/Appendix 4C Cash Flow Report Price sensitive	AI summary
28 Jul 2026, 9:39 AM	Quarterly Activities/Appendix 4C Cash Flow Report Price sensitive	AI summary
10 Jul 2026, 4:24 PM	Long Term Suspended Entities Price sensitive	AI summary
15 Jun 2026, 3:36 PM	Quarterly Appendix 4C Cash Flow Report Price sensitive	AI summary
14 May 2026, 11:58 AM	Final Director's Interest Notice - Bernecker
14 May 2026, 11:33 AM	Director Resignation - Bernecker
17 Apr 2026, 2:52 PM	Long Term Suspended Entities Price sensitive	AI summary
8 Apr 2026, 12:17 PM	Quarterly Appendix 4C Cash Flow Report Price sensitive	AI summary

Sign in to see all UCM announcements.

Guidance history

28 Jul 2026	nil revenue for Q4 2026, cash on hand $0.001m, operating cash outflow $0.187m
15 Jun 2026	Q3 cash inflow $3,000, cash on hand $1,000, expenditure reduced to $2,000
27 Feb 2025	Uscom expects its newly approved products in China, combined with the Sinopharm partnership, to begin boosting revenue in H2 FY25.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow UCM to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.